One platform for all researcher needs
AI-powered academic writing assistant
Your #1 AI companion for literature search
AI tool for graphics, illustrations, and artwork
Unlock unlimited use of all AI tools with the Editage All Access membership.
Explore Editage All Access
Search from 250 M+ research papersSearch from 250 M+ research papers
Open Accesshttps://doi.org/10.1182/blood-2019-131217
Copy DOI Journal: Blood |  Publication Date: Nov 13, 2019 |
 Citations: 19 |
Affiliation: University of Kansas Cancer Center, Ark Therapeutic (United States), Cornell University, Roswell Park Cancer Institute, Mayo Clinic, University Health Network, Princess Margaret Cancer Centre, City of Hope, The University of Texas MD Anderson Cancer Center, University of California, Los Angeles, Los Angeles Medical Center, University of Michigan–Ann Arbor, University of AlbertaResults from a Phase 1/2 Clinical Trial of Tagraxofusp (SL-401) in Patients with Intermediate, or High Risk, Relapsed/Refractory Myelofibrosis
Sign-in/Register to access full text options 
Free) Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
